296 related articles for article (PubMed ID: 28243883)
1. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
[TBL] [Abstract][Full Text] [Related]
2. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
4. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study.
Tremblay É; Perreault S; Dorais M
Arch Osteoporos; 2016 Dec; 11(1):30. PubMed ID: 27679503
[TBL] [Abstract][Full Text] [Related]
5. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
6. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
7. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Lee S; Glendenning P; Inderjeeth CA
Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
[TBL] [Abstract][Full Text] [Related]
9. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
10. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
Li L; Roddam A; Gitlin M; Taylor A; Shepherd S; Shearer A; Jick S
Menopause; 2012 Jan; 19(1):33-40. PubMed ID: 21926926
[TBL] [Abstract][Full Text] [Related]
11. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
12. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
14. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.
Karlsson L; Lundkvist J; Psachoulia E; Intorcia M; Ström O
Osteoporos Int; 2015 Oct; 26(10):2401-11. PubMed ID: 26282229
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang S; Pohl GM; Long SR
BMC Womens Health; 2008 Dec; 8():24. PubMed ID: 19105828
[TBL] [Abstract][Full Text] [Related]
16. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
[TBL] [Abstract][Full Text] [Related]
17. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
18. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH
Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
[TBL] [Abstract][Full Text] [Related]
19. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
20. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Siris ES; Modi A; Tang J; Gandhi S; Sen S
Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]